HeartMate 3 CE Mark Trial 1-Year Results Presented at ISHLT 36th Annual Meeting and Scientific Sessions in Washington, D.C.
28 avr. 2016 11h13 HE
|
International Society for Heart and Lung Transplantation
WASHINGTON, April 28, 2016 (GLOBE NEWSWIRE) -- At today's opening plenary session at the 36th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific Sessions,...
National Institutes of Health and Mesoblast Enter Into Agreement for 120-Patient Trial In End-Stage Heart Failure
06 août 2014 20h57 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the signing of an agreement with the United...
Improved Outcomes Using Mesoblast Cells in End-Stage Heart Failure
24 juin 2014 21h19 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 24, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that trial results evaluating a low dose...
Mesoblast's Cell Therapy Strengthens Native Heart Function In Patients With End-Stage Heart Failure on Assisted Circulatory Support
18 nov. 2013 18h14 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 18, 2013 (GLOBE NEWSWIRE) -- Patients with end-stage or New York Heart Association (NYHA) class IV heart failure who receive a surgically implanted left...
Sunshine Heart Announces Results of Its C-Pulse(R) Feasibility Trial at the Transcatheter Cardiovascular Therapeutics Conference
07 nov. 2011 08h00 HE
|
Sunshine Heart, Inc.
SYDNEY, AUSTRALIA and EDEN PRAIRIE, MN--(Marketwire - Nov 7, 2011) - Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for moderate to severe heart...
Sunshine Heart's Feasibility Trial Outcomes to Be Presented at Transcatheter Cardiovascular Therapeutics Conference
19 oct. 2011 05h00 HE
|
Sunshine Heart, Inc.
SYDNEY, AUSTRALIA and EDEN PRAIRIE, MN--(Marketwire - Oct 19, 2011) - Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for moderate heart failure,...
Sunshine Heart Appoints New US Board Member
03 août 2011 15h19 HE
|
Sunshine Heart, Inc.
SYDNEY, AUSTRALIA and EDEN PRAIRIE, MN--(Marketwire - Aug 3, 2011) - Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for moderate heart failure,...
Sunshine Heart Completes Feasibility Study for Fully-Implantable C-Pulse(R) Heart Assist System
08 juin 2011 18h53 HE
|
Sunshine Heart, Inc.
MINNEAPOLIS, MN--(Marketwire - Jun 8, 2011) - Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for Class III/ambulatory Class IV (moderate to...
Sunshine Heart Receives Approval to Expand C-Pulse(R) Heart Assist System Study
10 avr. 2011 19h00 HE
|
Sunshine Heart, Inc.
MINNEAPOLIS, MN--(Marketwire - Apr 10, 2011) - Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for Class III/ambulatory Class IV (moderate to...
Sunshine Heart Announces Completion of Enrollment of 20 Patients for C-Pulse(R) Heart Assist System
03 avr. 2011 19h00 HE
|
Sunshine Heart, Inc.
MINNEAPOLIS, MN--(Marketwire - April 3, 2011) - Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for moderate to severe heart failure, today...